<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31413051</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-790X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>BMJ case reports</Title><ISOAbbreviation>BMJ Case Rep</ISOAbbreviation></Journal><ArticleTitle>A man with polycythemia vera, myelodysplastic syndrome and acquired microcytosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e229695</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2019-229695</ELocationID><Abstract><AbstractText>A 59-year-old white man with known myeloproliferative neoplasm (MPN) and myelodysplastic syndrome (MDS) presented with worsening leucocytosis and thrombocytosis in the setting of a presumed infection. The patient had been diagnosed 2 years earlier with an MPN/MDS overlap syndrome, based on characteristic mutations in JAK2, IDH1 and SRSF2. During his current evaluation, he was noted to have new microcytosis, with a mean corpuscular volume of ~70&#x2009;fL down from his baseline of ~90&#x2009;fL. His laboratory workup showed normal iron studies, normal haemoglobin electrophoresis, and no evidence of haemoglobin H or mutations in his ATRX coding region. Without any identifiable cause of his new microcytosis, he was given a presumptive diagnosis of acquired thalassemia in the setting of his unusual MPN/MDS overlap syndrome.</AbstractText><CopyrightInformation>&#xa9; BMJ Publishing Group Limited 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medicine, SUNY Downstate Medical Center, Brooklyn, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreuzbauer</LastName><ForeName>Tania</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Medicine, University of Exeter Medical School, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sykes</LastName><ForeName>David B</ForeName><Initials>DB</Initials><Identifier Source="ORCID">0000-0002-9788-0221</Identifier><AffiliationInfo><Affiliation>Hematology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Case Rep</MedlineTA><NlmUniqueID>101526291</NlmUniqueID><ISSNLinking>1757-790X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001772" MajorTopicYN="N">Blood Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007964" MajorTopicYN="N">Leukocytosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054437" MajorTopicYN="N">Myelodysplastic-Myeloproliferative Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011087" MajorTopicYN="N">Polycythemia Vera</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">haematology (incl blood transfusion)</Keyword><Keyword MajorTopicYN="N">medical education</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31413051</ArticleId><ArticleId IdType="pmc">PMC6700592</ArticleId><ArticleId IdType="doi">10.1136/bcr-2019-229695</ArticleId><ArticleId IdType="pii">12/8/e229695</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mentzer WC. Differentiation of iron deficiency from thalassaemia trait. Lancet 1973;1:882 10.1016/S0140-6736(73)91446-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(73)91446-3</ArticleId><ArticleId IdType="pubmed">4123424</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLoughery TG. Microcytosis. N Engl J Med 2014;371:1324&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">25271605</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohlman F, Ebbe S, Morse B, et al. . Regulation of erythropoiesis. XX. Kinetics of red cell production. Ann N Y Acad Sci 1968;149(1):156&#x2013;72. 10.1111/j.1749-6632.1968.tb15149.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1968.tb15149.x</ArticleId><ArticleId IdType="pubmed">5240705</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabath DE. Molecular Diagnosis of Thalassemias and Hemoglobinopathies. Am J Clin Pathol 2017;148:6&#x2013;15. 10.1093/ajcp/aqx047</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqx047</ArticleId><ArticleId IdType="pubmed">28605432</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensma DP. Myelodysplastic Syndromes: Diagnosis and Treatment. Mayo Clin Proc 2015;90:969&#x2013;83. 10.1016/j.mayocp.2015.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2015.04.001</ArticleId><ArticleId IdType="pubmed">26141335</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensma DP, Gibbons RJ, Higgs DR, et al. . Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood 2005;105:443&#x2013;52. 10.1182/blood-2004-07-2792</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-07-2792</ArticleId><ArticleId IdType="pubmed">15358626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanasaki M, Higuchi T, Kawamoto K, et al. . Acquired &#x3b2;-Thalassemia as an Etiology of Microcytic Anemia in Primary Myelofibrosis. Journal of Hematology 2015;4:148&#x2013;50. 10.14740/jh190w</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jh190w</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensma DP, Higgs DR, Fisher CA, et al. . Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood 2004;103:2019&#x2013;26. 10.1182/blood-2003-09-3360</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2003-09-3360</ArticleId><ArticleId IdType="pubmed">14592816</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson ME, Thurmes PJ, Hoyer JD, et al. . A novel 5' ATRX mutation with splicing consequences in acquired alpha thalassemia-myelodysplastic syndrome. Haematologica 2005;90:1463&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">16266892</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa DB, Fisher CA, Miller KB, et al. . A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome. Eur J Haematol 2006;76:432&#x2013;5. 10.1111/j.1600-0609.2006.00628.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0609.2006.00628.x</ArticleId><ArticleId IdType="pubmed">16480427</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbaux C, Duployez N, Badens C, et al. . Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis. Am J Hematol 2015;90:737&#x2013;8. 10.1002/ajh.24073</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.24073</ArticleId><ArticleId IdType="pubmed">26017030</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons RJ, Wada T, Fisher CA, et al. . Mutations in the chromatin-associated protein ATRX. Hum Mutat 2008;29:796&#x2013;802. 10.1002/humu.20734</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.20734</ArticleId><ArticleId IdType="pubmed">18409179</ArticleId></ArticleIdList></Reference><Reference><Citation>Fermo E, Zaninoni A, Imperiali FG, et al. . Analysis of JAK2 V167F Mutation in Myelodysplastic Syndromes. Blood 2007;110:4591.</Citation></Reference><Reference><Citation>Davids MS, Steensma DP. The molecular pathogenesis of myelodysplastic syndromes, Cancer Biology &amp; Therapy. 2010;10:4:309&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">20592488</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>